CAS No.:96829-58-2
MF:C29H53NO5
EINECS No.:96829-58-2
Place of Origin:China (Mainland)
Packaging Details:25kg drum
Specification:
| Product Name | Orlistat |
| Package | 25KG Bag |
| Specific rotation | -48.0°~ -51.0°(on the anhydrous, solvent-free basis) |
| Identification | A HPLC The retention time of the major peak of the sample solution corresponds to that of the standard solution. B IR The IR spectrum of sample is consistent to the reference standard. |
| Appearance | White to off-white fine powder or fine powder with lumps |
| Related Substances | |
| Total impurity | ≤1.0% |
| Related Compound A  | ≤0.2% |
| Related Compound B | ≤0.05% |
| Related Compound C | ≤0.05% |
| Related Compound D | ≤0.2% |
| Related Compound E | ≤0.2% |
| Formylleucine | ≤0.2% |
| Orlistat open ring epimer  | ≤0.2% |
| D-Leucine orlistat | ≤0.2% |
| Orlistat open ring amide | ≤0.1% |
| Individual unidentified impurity | ≤0.1% |
| Residual Solvents | |
| N-heptane | ≤5000ppm |
| Isopropyl ether | ≤5000ppm |
| Methanol | ≤3000ppm |
| Tetrahydrofuran | ≤720ppm |
| Residual on ignition | ≤0.1% |
| Heavy metals | ≤20ppm |
| Assay | 98.0%~101.5%(on the anhydrous,solvent-free basis) |
| Water | ≤0.2% |
USE:
Orlistat is currently the best-selling weight loss products.
Orlistat is a potent and long-acting specific inhibitor of gastrointestinal lipase, by directly blocking the body's absorption of fat in the food intake of energy consumption and fat than once, natural reduction of body fat, so as to achieve the purpose of weight loss. It is safe to lose weight, the active ingredient does not enter the blood circulation, do not act on the central nervous system, with fewer side effects, no dizziness, palpitation, insomnia, dry mouth, and so on.
 ORLISTAT LOSE WEIGHT ORLISTAT
CAS No.:96829-58-2
MF:C29H53NO5
EINECS No.:96829-58-2
Place of Origin:China (Mainland)
Packaging Details:25kg drum
Specification:
| Product Name | Orlistat |
| Package | 25KG Bag |
| Specific rotation | -48.0°~ -51.0°(on the anhydrous, solvent-free basis) |
| Identification | A HPLC The retention time of the major peak of the sample solution corresponds to that of the standard solution. B IR The IR spectrum of sample is consistent to the reference standard. |
| Appearance | White to off-white fine powder or fine powder with lumps |
| Related Substances | |
| Total impurity | ≤1.0% |
| Related Compound A  | ≤0.2% |
| Related Compound B | ≤0.05% |
| Related Compound C | ≤0.05% |
| Related Compound D | ≤0.2% |
| Related Compound E | ≤0.2% |
| Formylleucine | ≤0.2% |
| Orlistat open ring epimer  | ≤0.2% |
| D-Leucine orlistat | ≤0.2% |
| Orlistat open ring amide | ≤0.1% |
| Individual unidentified impurity | ≤0.1% |
| Residual Solvents | |
| N-heptane | ≤5000ppm |
| Isopropyl ether | ≤5000ppm |
| Methanol | ≤3000ppm |
| Tetrahydrofuran | ≤720ppm |
| Residual on ignition | ≤0.1% |
| Heavy metals | ≤20ppm |
| Assay | 98.0%~101.5%(on the anhydrous,solvent-free basis) |
| Water | ≤0.2% |
USE:
Orlistat is currently the best-selling weight loss products.
Orlistat is a potent and long-acting specific inhibitor of gastrointestinal lipase, by directly blocking the body's absorption of fat in the food intake of energy consumption and fat than once, natural reduction of body fat, so as to achieve the purpose of weight loss. It is safe to lose weight, the active ingredient does not enter the blood circulation, do not act on the central nervous system, with fewer side effects, no dizziness, palpitation, insomnia, dry mouth, and so on.
Â
The characteristics of POCT devices determine that they can play an important role in primary medical institutions. In order to standardize and strengthen the application of on-site rapid testing in primary medical and health institutions, promote the rational allocation, safe and effective use of POCT in primary medical and health institutions, give full play to its use value, and ensure the healthy development of medical and health services, "On-site Point-of-care Testing (POCT) Primary The Expert Consensus on the Application of Medical and Health Institutions (hereinafter referred to as the "Consensus") came into being. The consensus was published in the 2019 "China Medical Equipment" magazine after first draft writing, 2 expert on-site discussions, 2 expert online review meetings, and 3 submission revisions. The formulation of the consensus will greatly promote the management standards of the POCT industry, continuously increase the training of grass-roots personnel, deeply understand the application requirements of POCT at the grass-roots level, and promote the rapid development of the POCT industry.
Point-of-care testing (POCT) represents a fruitful method in today's hospitals in terms of patient care and cost management. Its application enables some of the testing items originally undertaken by the central laboratory to be transferred to the clinical departments and patient beds that need it. side. For blood gas analysis technology, POCT has shown great advantages.
Our blood gas analyzer is small and portable, beautiful in appearance, accurate in results and good in stability. It is a blood gas analysis platform with both appearance and strength. It can be used not only in the central laboratory department, but also at the bedside of patients to meet the bedside detection needs of clinical departments such as hospital ICU, emergency, anesthesia, respiratory, neurology, etc. It realizes true POCT blood gas analysis and provides more advantageous assistance for clinical practice. Diagnostic Services.
Portable Analyzer for Blood Fat,Home Care Blood Glucose Meter,Best Blood Glucose Meter,Blood Glucose Meter Device
Jilin Sinoscience Technology Co. LTD , https://www.contoryinstruments.com